US stock movement | Zai Ding Pharmaceutical (ZLAB.US) surged over 12% as Q2 product revenue increased by 11% quarter-on-quarter.

Zhiyuan Finance APP reported that on Thursday, Zai Ding Pharmaceutical (ZLAB.US) surged over 12% to $20.68. In terms of news, Zai Ding Pharmaceutical announced its financial results for the second quarter of 2026. The financial report indicates that total revenue for the second quarter of 2026 was $106.3 million, with net product revenue of $105.8 million, reflecting a quarter-on-quarter increase of 11%, thanks to the stable performance of Zele and the continued growth in sales of Aigamod.